Contineum Therapeutics, Inc. Class A Common Stock CTNM
Analyst Ratings
- Consensus
- Buy — 3 Buy · 1 Hold · 0 Sell (4 analysts)
- Avg. Price Target
- $20.75 (+142.3% upside)
Key Stats
- Today's Range
- $8.43 – $11.54
- 50-Day Range
- $8.43 – $17.79
- 52-Week Range
- $8.43 – $17.79
- Volume
- 8.47 million shs
- Average Volume
- 916K shs
- Market Cap
- $503.37 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 1.59%
- Days to Cover
- 2.33
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Related Stocks
Compare head-to-head: CTNM vs LLY·CTNM vs JNJ·CTNM vs ABBV·CTNM vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.